EGFR and non-small cell lung carcinoma: In patients with EGFR‐mutant NSCLC showing CNS progression on 80 mg/day osimertinib, dose escalation to 160 mg resulted in moderate efficacy, with CNS control lasting approximately between 3 and 6 months.17